Literature DB >> 8960994

Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia.

M Shaarawy1, H E Didy.   

Abstract

OBJECTIVE: Preeclampsia has been recently suggested to be an endothelial cell disorder. This study was initiated to determine the levels of various biomarkers of endothelial damage in preeclampsia and eclampsia.
METHODS: Blood samples were withdrawn from 70 pregnant women in their third trimester grouped as 25 mild preeclampsia, 15 severe preeclampsia, 10 eclampsia and 20 normotensive healthy women (controls) for the determination of thrombomodulin by ELISA, PAI-1 by urokinase method and fibronectin by radial immunodiffusion. Results were statistically analyzed by Student's t-test.
RESULTS: Circulation levels of PAI-1, thrombomodulin and fibronectin were increased with increasing severity of the disease. Thrombomodulin was the only parameter which did not change significantly in mild preeclampsia. The average percent increments in preeclampsia and eclampsia were 63%, 102% and 132%, respectively.
CONCLUSIONS: These results demonstrate that fibronectin may be a more valuable biomarker than thrombomodulin and PAI-1 for the assessment of endothelial damage in preeclampsia and eclampsia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960994     DOI: 10.1016/s0020-7292(96)02755-5

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  9 in total

Review 1.  Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia.

Authors:  Yang Xia; Susan M Ramin; Rodney E Kellems
Journal:  Hypertension       Date:  2007-06-18       Impact factor: 10.190

2.  Intraabdominal fat, insulin sensitivity, and cardiovascular risk factors in postpartum women with a history of preeclampsia.

Authors:  Darcy R Barry; Kristina M Utzschneider; Jenny Tong; Kersten Gaba; Daniel F Leotta; John D Brunzell; Thomas R Easterling
Journal:  Am J Obstet Gynecol       Date:  2015-05-21       Impact factor: 8.661

3.  Renin angiotensin signaling in normal pregnancy and preeclampsia.

Authors:  Roxanna A Irani; Yang Xia
Journal:  Semin Nephrol       Date:  2011-01       Impact factor: 5.299

4.  Proteomic analysis of human serum for finding pathogenic factors and potential biomarkers in preeclampsia.

Authors:  C Liu; N Zhang; H Yu; Y Chen; Y Liang; H Deng; Z Zhang
Journal:  Placenta       Date:  2010-12-08       Impact factor: 3.481

Review 5.  Preeclampsia and the future risk of hypertension: the pregnant evidence.

Authors:  Vesna D Garovic; Phyllis August
Journal:  Curr Hypertens Rep       Date:  2013-04       Impact factor: 5.369

Review 6.  Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test?

Authors:  Iasmina Craici; Steven Wagner; Vesna D Garovic
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-08

Review 7.  A Dormant Microbial Component in the Development of Preeclampsia.

Authors:  Douglas B Kell; Louise C Kenny
Journal:  Front Med (Lausanne)       Date:  2016-11-29

8.  Fibrinolytic Changes in Women with Preeclampsia.

Authors:  Anne Cathrine Godtfredsen; Johannes Jakobsen Sidelmann; Britta Blume Dolleris; Jan Stener Jørgensen; Emma Kathrine Jungjohan Johansen; Melissa Fernard Bøg Pedersen; Yaseelan Palarasah; Jørgen Brodersen Gram
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

9.  The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia.

Authors:  Roxanna A Irani; Yujin Zhang; Sean C Blackwell; Cissy Chenyi Zhou; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  J Exp Med       Date:  2009-11-02       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.